Tilray | TRLY - Selling And Administration Expenses


Tilray reported $24.85M in Selling and Administration Expenses for its fiscal quarter ending in September of 2025.





Selling And Administration Expenses Change Date
Acasti Pharma USD 1.96M 180K Sep/2025
Akebia Therapeutics USD 23.53M 3.19M Dec/2025
Alaunos Therapeutics USD 424K 23K Jun/2026
Aurora Cannabis CAD 40.89M 515K Jun/2026
Avita Medical AUD 19.54M 516K Jun/2026
Canopy Growth CAD 33.99M 2.83M Jun/2026
Cronos Group USD 19.14M 1.55M Sep/2026
Dianthus Therapeutics USD 13.56M 1.09M Jun/2026
Divis Laboratories Ltd INR 3.4B 10M Jun/2025
Ionis Pharmaceuticals USD 154M 23.92M Sep/2026
IQVIA Holdings USD 569M 5M Sep/2026
Knight Therapeutics CAD 35.45M 4.43M Dec/2025
Moderna USD 282M 66M Sep/2026
Organigram Holdings CAD 26.51M 4.5M Jun/2026
Organon & Co USD 407M 27M Sep/2026
Revvity USD 275.33M 3.25M Sep/2026
Tectonic Therapeutic USD 6.17M 260K Jun/2026
Tilray USD 24.85M 1.7M Sep/2025
Viatris USD 950.8M 183.7M Sep/2026
Xeris Pharmaceuticals USD 61.04M 7.89M Jun/2026
Zealand Pharma A/S 104M 12.19M Mar/2026